IMVT (Immunovant) Days Sales Outstanding : 0.00 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Immunovant Days Sales Outstanding?

Immunovant's average Accounts Receivable for the three months ended in Sep. 2024 was $2.15 Mil. Immunovant's Revenue for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Immunovant's Days Sales Outstanding or its related term are showing as below:

IMVT's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 70.71
* Ranked among companies with meaningful Days Sales Outstanding only.

Immunovant's Days Sales Outstanding stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Immunovant Days Sales Outstanding Historical Data

The historical data trend for Immunovant's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Days Sales Outstanding Chart

Immunovant Annual Data

Trend

Dec18

Mar20

Mar21

Mar22

Mar23

Mar24

Days Sales Outstanding

Get a 7-Day Free Trial

Immunovant Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immunovant's Days Sales Outstanding

For the Biotechnology subindustry, Immunovant's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovant's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Immunovant's Days Sales Outstanding falls into.

Immunovant Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Immunovant's Days Sales Outstanding for the fiscal year that ended in Mar. 2024 is calculated as

	Days Sales Outstanding (A: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0.7	+	5.337)	/	2 )	/	0	*	365
=	3.0185					/	0	*	365
=	N/A

Immunovant's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding (Q: Sep. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )	/	Revenue (A: Sep. 2024 )	*	Days in Period
=	( (2.417	+	1.876)	/	2 )	/	0	*	365 / 4
=	2.1465					/	0	*	365 / 4
=	N/A

Immunovant (NAS:IMVT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Immunovant Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Immunovant's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 West 37th Street, 6th Floor, New York, NY, USA, 10018

Website

https://www.immunovant.com

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Executives

Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Douglas J. Hughes	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William L. Macias	officer: Chief Medical Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett	officer: Chief Financial Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Mark S. Levine	officer: Chief Legal Officer	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Peter Salzmann	director, officer: Chief Executive Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jay S Stout	officer: Chief Technology Officer	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Julia G. Butchko	officer: Chief Dev. & Tech. Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Frank Torti	director	2855 SAND HILL ROAD, MENLO PARK CA 94025
Rita Jain	officer: Chief Medical Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott	officer: Chief Scientific Officer	320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018